News Column

Findings on Glioblastomas Reported by Investigators at University of Amsterdam (Nanoparticles for hyperthermic therapy: synthesis strategies and...

July 23, 2014



Findings on Glioblastomas Reported by Investigators at University of Amsterdam (Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma)

By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Oncology are presented in a new report. According to news reporting out of Amsterdam, Netherlands, by NewsRx editors, research stated, "Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. Current GBM treatment includes surgery, radiation therapy, and chemotherapy, sometimes supplemented with novel therapies."

Our news journalists obtained a quote from the research from the University of Amsterdam, "Despite recent advances, survival of GBM patients remains poor. Major challenges in GBM treatment are drug delivery across the blood-brain barrier, restriction of damage to healthy brain tissues, and limitation of resistance to therapies. This article reviews recent advances in the application of magnetic nanoparticles (MNPs), gold nanorods (GNRs), and carbon nanotubes (CNTs) for hyperthermia ablation of GBM. First, the article introduces GBM, its current treatment, and hyperthermia as a potential modality for the management of GBM. Second, it introduces MNPs, GNRs, and CNTs as inorganic agents to induce hyperthermia in GBM. Third, it discusses different methodologies for synthesis of each inorganic agent."

According to the news editors, the research concluded: "Finally, it reviews in vitro and in vivo studies in which MNPs, GNRs, and CNTs have been applied for hyperthermia ablation and drug delivery in GBM."

For more information on this research see: Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma. International Journal of Nanomedicine, 2014;9():2863-2877. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Oncology).

Our news journalists report that additional information may be obtained by contacting J. Verma, University of Amsterdam, Academy Med Center, Cell Biol & Histol Lab, NL-1105 AZ Amsterdam, Netherlands. Additional authors for this research include S. Lal and C.J.F. Van Noorden.

Keywords for this news article include: Europe, Therapy, Oncology, Amsterdam, Netherlands, Glioblastoma, Nanoparticle, Nanotechnology, Emerging Technologies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters